ADIL | Adial Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.9924 - 1.0200
52 Week Range	0.7700 - 4.17
Beta	1.27
Implied Volatility	536.10%
IV Rank	100.00%
Day's Volume	96,596
Average Volume	149,187
Shares Outstanding	6,405,780
Market Cap	6,533,896
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-07-27

Valuation
Profitability
Growth
Health
P/E Ratio	-0.35
Forward P/E Ratio	N/A
EPS	-2.94
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	4
Country	USA
Website	ADIL

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

ADIL's peers: RNAZ, ADTX, RVPH, ATXI, AMTI, CBIO, ALRN, BPTH, BNTC, HOTH, REVB, NRBO, VRAX, RNXT, AXLA, BTTX, KTTA, ONTX, DFFN, AEZS, TNXP, ATHE, CANF, ITRM, NNVC

*Chart delayed

Analyzing fundamentals for ADIL we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see ADIL Fundamentals page.

Watching at ADIL technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ADIL Technicals page.